This webinar will briefly review the science and pharmacology that led to the development of ketamine and esketamine as a treatment for neuropsychiatric disorders. It will specifically focus on major issues to be contemplated when considering recommending treatment with ketamine or esketamine to treat severe and persistent major depressive disorder. We will critically review the existing data from a wide range of clinical trials and attempt to incorporate this data into clinical decision making processes.

Presenter: Gerard Sanacora, PhD, MD, Yale University

For complete details visit: SMIadviser.org/ketamine

Experience the meeting of the profession. Join more than 2,000 social workers, like-minded professionals, and social work thought leaders for four days of unparalleled opportunities for professional development, continuing education, networking, and thought-provoking conversations tackling the most pressing issues facing the social work profession across the world.